MTNB
Matinas BioPharma Holdings Inc
Price:
1.03
USD
Volume:
75,151
United States | Biotechnology
No data available for this ticker
MTNB Probability of Bankruptcy
The Probability of Bankruptcy of Matinas BioPharma Holdings Inc (MTNB) is 0% . This number represents the probability that MTNB will face financial distress in the next 24 months given its current fundamentals and market conditions.
Multiple factors are taken into account when calculating MTNB's probability of bankruptcy : Altman Z-score, Beneish M-score, financial position, macro environments, academic research about distress risk and more.
MTNB - Historical Solvency Measures
to of
Page of
MTNB - ESG ratings
ESG ratings are directly linked to the cost of capital and MTNB's ability to raise funding, both of which can significantly affect the probability of Matinas BioPharma Holdings Inc going bankrupt.
ESG Score
20.88
Environment Score
23.7
Social Score
14.25
Governance Score
24.7
| Returns | |
| Historical Returns (5 day) | 11.96% |
| Historical Returns (MTD) | 15.73% |
| Historical Returns (YTD) | 101.96% |
| Historical Returns (13 week) | 100.82% |
| Historical Returns (26 week) | 75.17% |
| Historical Returns (52 week) | -69.57% |
| Efficiency | |
| Asset Turnover | 0.09 |
| Receiveable Turnover | - |
| Gross Margin | - |
| Operating Margin | - |
| Pretax Margin | - |
| Net Margin | - |
| Return on Asset (ROA) | -125.66 |
| Return on Equity (ROE) | -170.09 |
| Return on Investments (ROI) | -169.86 |
| Price Metrics | |
| Market Cap (M) | 5.2 |
| Enterprise Value (M) | -1.7 |
| 52 Week High | 9.6 |
| 52 Week Low | 0.47 |
| Beta | 1.32 |
| Average Volume (10 day) | 0.07 |
| Average Volume (3 month) | 0.19 |
| Price / Earnings (P/E) | - |
| Price / Sales (P/S) | 1.2 |
| Earnings | |
| EPS | -4.99 |
| Revenue CAGR (5 year) | - |
| Risk | |
| Current Ratio | 3.35 |
| Quick Ratio | 3.09 |
MTNB - Peer Comparisons
| Ticker | Company Name | Beta | Probability of Bankruptcy |
| a | |||
| CELC | Celcuity Inc | 1.39 | 47% |
| FENC | Fennec Pharmaceuticals Inc | 2.12 | 23.7% |
| GRCL | Gracell Biotechnologies Inc | 1.99 | 75.8% |
| XFOR | X4 Pharmaceuticals Inc | 0.8 | 80% |